- Albany Med Health System eyes affiliation with Ellis Medicine
- 1.4 million patients, 7 health systems caught in AI company data breach
- Banner Health clinicians file to unionize
- New Hampshire system names new chief strategy officer
- 8 recent studies on AI in diagnosis and clinical reasoning
- HHS launches Operation TrailBlazer to speed clinical trials: 5 notes
- Iowa 1st to fully allocate year 1 rural health funds
- ‘I would love to tell Mark Cuban to get involved’: What physician consolidation is costing patients
- Illinois passes bill regulating dental reimbursement practices
- The shifting dental care landscape
- Duke Health names ophthalmology chair
- Health insurer CEOs could face criminal liability for denials that lead to injury, death under Pennsylvania bill
- Texas hospital taps new COO
- Harvard to end faculty dental practice, transfer clinic to private owner due to financial constraints
- A physician’s plan to bring back practice autonomy to South Carolina
- Cardiologists push back on expansion of WISeR model
- Are ASCs ready for CMS’ new oversight rules?
- MCNA Dental agrees to multimillion-dollar settlement over 2023 ransomware attack
- Former Iowa dental office employee accused of using patient financial information for personal purchases
- Optum Behavioral Health names chief medical officer
- Stark law’s $632 million reckoning: The 5 biggest cases in 5 years
- ASCs’ robot evidence problem
- United Concordia expands dental coverage for patients with chronic conditions
- Who’s winning, losing the physician practice acquisition race?
- OIG flags Pennsylvania behavioral insurer for faulty prior auth denials
- Independence Health to open 28-bed behavioral health unit
- ICON Dental Partners appoints VP of dental partnerships
- These 'socially responsible' hospitals deliver on quality, value and equity
- Heartland Dental adds Missouri practice
- 4 dentists making headlines
- Growing ketamine use raises safety concerns
- AI’s growing role in mental healthcare: 5 notes
- Does ASC consolidation have a ceiling?
- Washington lawmakers eye corporate medicine ban after Oregon’s PeaceHealth test
- Pennsylvania cardiology group opens new $8.2M ASC
- Patient portal messages doubled since 2020, study finds, underscoring challenges to physician workloads
- Clover Hill Dairy Recalls All Cheese in Deadly Listeria Outbreak
- Ensemble Health Partners secures strategic growth investment from Thoreau
- Hospital margins inched higher in April, but still remain below 2025
- Middle-Aged Women Drink More, Know Less About Breast Cancer Risk
- CMS Proposes TAVR Medicare Coverage is Potential Boost for Edwards Lifesciences
- CARsgen makes history as China approves world's first CAR-T therapy for solid tumors
- High Hurdles Thwart Kidney Patients' Pursuit Of Life-Saving Transplants
- Rising Healthcare Costs Leave Many Americans Less Secure
- Short Videos Help First-Time Dads Learn Newborn Safety Basics
- Federal Push To Increase U.S. Primary Care Docs Has Fizzled, Study Says
- US to investigate Germany's proposed drug spending reforms
- Alnylam scolded over promotional activity after Pfizer complaint
- They're Uninsured After Obamacare Became Too Costly. And They're Far From Alone.
- Indiana Takes On Powerful Hospitals by Capping Prices They Charge Employers
- Prosper AI lands $30M backed by Andreessen Horowitz to build AI workforce for healthcare operations
- Eli Lilly, Novo Nordisk top AI citation share as new report questions DTC spend culture
- Fish Oil Supplements May Be A Bust For Alzheimer's Prevention
- Prehab Can Boost Seniors' Recuperation From Spinal Fusion Surgery, Trial Finds
- Dog Owners Feel Similar Grief Whether Pets Euthanized, Die Naturally
- Ozempic Might Cut Risk Of Broken Bones, Study Says
- Massage Guns Can Cause Eye Damage, Vision Loss, Case Report Warns
- A 5-month sprint: Behind Pfizer’s $10B deal and Innovent’s global pharma ambition
- 1st free dental clinic opens in New Jersey
- 8 new behavioral health projects to know
- Oregon prosecutors urge state to fix mental health system
- The case for layering behavioral healthcare models
- Rural, independent Kansas hospitals launch clinically integrated network
- 12 behavioral health services, facility closures | 2026
- Higher, short-acting opioid doses linked to 8% lower discharge risk: 4 notes
- FTC orders Aurobindo to divest 4 drugs to complete $250M Lannett acquisition
- Congressional Budget Office calls for more research on No Surprises Act unintended impacts
- HHS opens applications for $700M in mental health, addiction funding, with $96M for new STREETS program
- Ebola Infections Climb, Could Take Year To Contain, Health Officials Say
- Why a deviation investigation still takes two weeks in the age of AI
- Feeling Sleepy During the Day? It Could Be a Warning Sign for High Blood Pressure
- FTC, states sue transgender health association over 'misleading' gender care guidance
- Healthcare organizations still struggle to operationalize AI at scale: Arcadia survey
- Pfizer hunts for new CFO as Denton prepares to hang up gloves, wave goodbye to pharma
- Major League Pitchers Might Avoid Elbow Injuries By Altering Their Approach, Simulation Suggests
- Birth Control Pills Might Increase Binge Eating Risk, Study Finds
- Women Might Lower Their Heart Risk By Lifting Weights, Study Says
- Personalized Brain Implant Provides Step-By-Step Walking Boost For Parkinson's Patients
- Amid industry’s cell therapy automation push, Cellares and Ori dominate the field: report
- Most Americans Are Surviving Cancer. But The Mental Health Challenges Can Persist.
- Listen to the Latest ‘KFF Health News Minute’
- Sandwiched Between Caring for Kids and Aging Parents? Reach Out for Resources
- Arrests of Immigrant Parents Create Mental Health Crisis for Children
- Readers Curse Medical Debt and Defend Spelling Therapy
- Novo's success with oral Wegovy has been fueled by 'familiarity': Spherix
- Preparing for LEAD: Why post-acute visibility is the key to long-term value-based success
- One Medical Seniors reports data breach of third-party vendor impacting 'limited' number of patients
- A look at Epic's long-term play to build tech for operations, starting with scheduling
- U.K. Moves To Ban Social Media For Children
- Pregnant Woman Exposed to 45 Common Chemicals, Study Finds
- OhioHealth reaches settlement with DOJ, Ohio AG on antitrust lawsuit
- 4 years after snub, GSK partnership helps Spero get Utebzi across FDA finish line
- Despite 'decent' data, Verastem rethinks options for approved oncology combo in pancreatic cancer
- OIG report raises red flags about maternal health 'ghost networks' in Medicaid managed care
- Why It’s Time to Sunset AI Point Solutions and Consolidate Platforms
- Lantern, Marathon Health team up to launch integrated care management model
- The New Frontier of Care Management: Bridging the Empathy Gap with Intelligence
- Novo Nordisk opens Czech plant and unveils $29M upgrade to China facility
- Whoop, HealthEx partner to connect members’ medical records and biometric data
- GSK runs first DTC ad for would-be asthma blockbuster Exdensur
- Novo security breach claimed by hacking groups seeking multi-million-dollar ransoms: reports
- After FDA sign-off, Colorado's drug import plan faces tough road ahead
- Lower Risk Of Death, Clots Among Autoimmune Patients Taking GLP-1 Drugs
- Surgical Menopause Tied To Worse Sexual And Urinary Symptoms
- Post-Op Delirium Common In Seniors, But Not All Hospitals Screen For It
- Nortiva purrs into action with long-acting Lynx platform salvaged from Langer startup
- Why one life insurer is going big on health incentives
- Weekly Rundown: Lumeris adds symptom-checking tool to AI platform; DeepIntent rolls out agentic AI tool for healthcare marketers
- Before you build or buy care navigation AI, answer this
- Early-Onset Cancers Are On The Rise. Knowing Your Family History Is Crucial.
- Minimally Invasive Procedure Eases Arthritis Knee Pain, Study Finds
- Tennessee Pharmacies Sell Potent Ivermectin, Led by Anti-Vaccine Doctor Who’s Taken ‘Bucketloads’
- Democrats Seek To Spotlight Rising Health Costs by Forcing Vote on Trump Regulation
- More Americans Are Surviving Cancer. But the Mental Health Challenges Can Persist.
- Health services deal value holds steady in 2026 with higher bar for investment: PwC
- Big Pharma’s Big Brand: Inside Eli Lilly’s marketing culture
- CDC, FDA Tackle New World Screwworm, Including Drug Authorization
- 'Biopharma ecosystem is back to full health,' fueled by M&A: PwC
- Lifestyle Changes Can Reduce Your Risk For Multiple Chronic Diseases
- FDA, UK drug regulator deepen transatlantic ties with new liaison program
- People Walk, Exercise Less After Starting Ozempic, Zepbound
- Family Finances Shape Children’s Brain Development, Study Finds
- At-Home Blood Pressure Monitoring Reduces Risk of Heart Attack, Stroke
- Moderna hires Novartis vet to lead commercial, upsizes role for Hoge as potential launches loom
- Long-Awaited Rule Aims To Boost ACA Choices While Embracing Higher Deductibles
- Many Men Are Prescribed Testosterone Without Proper Testing
- Early-Onset Cancers Are on the Rise. Knowing Your Family History Is Crucial.
- Backed by Threat of Clawbacks, Feds Wield Tight Grip on $50B Rural Health Fund
- Recipharm channels ‘multi-million-dollar' US manufacturing upgrade, targeting domestic biologics demand
- Organic Baby Formula Recalled Following Botulism Cases
- FDA Approves First Over-the-Counter Glucose Monitor for Children, The Stelo Glucose Biosensor System
- You've Won The Game
- Many Patients Stop And Restart GLP-1 Meds, Study Finds
- Half Of U.S. Parents Track Their Adult Children’s Location
- Taking GLP-1s While On BP Meds May Up Your Risk Of Dizzy Spells, Fainting
- Trust In CDC Plummets Under Trump Administration, New Poll Shows
- Remarks to the US-CEE Connection: Transatlantic Challenges in Law, Business & Policy
- Statement Regarding Minimum Pricing Increments and Access Fee Caps
- Statement at the SEC Open Meeting on the Trade-Through Rule and Locked and Crossed Markets Provisions of Regulation NMS
- Disorder Protection Rule: Statement on the Proposed Amendments to Rule 611 and Other Provisions of Regulation NMS
- Statement on the Proposed Amendments to Regulation NMS
- Beyond China and Japan: How biopharma is expanding rare disease access across Asia-Pacific
- This Old House: Improving and Remodeling Our Registered Offering and Filer Status Regimes
- Peirce Out: Remarks at the U.S. Chamber of Commerce Capital Markets Summit
- Medtronic Advances Hugo Robotic Surgery Platform with Key FDA Filings and Product Approvals
- Medtronic Posts Strongest Revenue Growth in a Decade, Driven by Cardiovascular and Surgical Businesses
- Boston Scientific Plans Indiana Distribution Center, 300 New Jobs
- “Harmonization: We’ll Have Lots to Talk About”
- Remarks at the Investor Advisory Committee Meeting
- A Quarter for Your Thoughts: Remarks at the Meeting of the SEC Investor Advisory Committee
Michigan healthcare freedom community forum
An Ohio telehealth company called Hims and Hers Health introduced a compounded, $ 49 per month GLP-1 agonist pill to the market yesterday and chaos has reigned in the pharmaceutical space ever since:
Exclusive: Hims offers cheapest GLP-1 weight-loss pill in US in a shock to Novo, Lilly
By Amina Niasse - February 5, 2026Summary
- Hims and Hers Health will offer the drugs at a price $100 cheaper than the brand-name offerings
- Novo Nordisk shares fall to lowest level since 2021
- Novo says it is considering legal action
NEW YORK, Feb 5 (Reuters) - Online telehealth company Hims and Hers Health (HIMS.N) on Thursday began offering a much cheaper $49 compounded version of Novo Nordisk's (NOVOb.CO) new Wegovy weight-loss pill in a move that expands sales to many Americans but could undercut Novo's and Eli Lilly's (LLY.N) plans for the consumer market.
The news touched off a swift reaction on Wall Street as investors sold off Novo and Lilly shares, and the Danish drugmaker promised a legal challenge to the move by Hims. Novo shares fell 8.6%, while Lilly was off (LLY.N) 6%.
Hims' pricing, $49 for the first month and $99 afterwards for those who purchase a five-month plan, makes their GLP-1 drug as affordable as monthly internet or streaming services in the U.S. It can offer access to treatment for many more of the estimated 200 million Americans who are overweight or obese.
It is $100 less than Novo, which launched its pill in January at $149 for first-time users and $199 after that. Lilly is expected to launch its pill in April and has promised the Trump Administration affordable pricing including on its new TrumpRx site.
Hims' move came after Novo warned on Wednesday that pricing pressure was unprecedented for its weight-loss medicines and dropped its full-year forecast. Novo shares on Thursday hit their lowest level since July 2021.
NOVO SAYS ITS PILL IS UNIQUE
Novo CEO Mike Doustdar in a meeting with investors on Thursday said people spending $49 on a Hims' pill would be wasting their money and that Novo's pill uses unique technology that aids in the absorption of the medicine.
Novo spokeswoman Ambre James-Brown described Hims' mass compounding as illegal. "Novo Nordisk will take legal and regulatory action to protect patients, our intellectual property and the integrity of the U.S. gold-standard drug approval framework," she said.
A Hims spokesperson said it has not compromised on safety or efficacy and that the company uses a technology based on liposomes that is intended to support absorption.
Analysts questioned if customers would get similar results on the cheaper pill but said it could drive a price war if compounders can provide an oral drug in large quantities.
Hims has been tussling with Novo since it was allowed in 2023 by the U.S. Food and Drug Administration to sell versions of Novo's GLP-1 injectible drugs while the branded medicines were in short supply. Since then, it has made "personalized" copies of the branded drugs at different doses or regimens than those available from Novo and other drug companies.
These drugs are not FDA approved and are subject to limited agency oversight. They also do not go through clinical trials to prove efficacy. Novo's Wegovy pill showed weight loss of more than 16% in trials.
"The status quo for months now has been a compounder can create a copycat version of a branded drug, so long as they make some kind of minor tweak that they believe or they argue benefits specific patient groups," said TD Cowen analyst Michael Nedelcovych.
HIMS MAKES CASE FOR MORE CHOICE
Hims said the treatment can be tailored for patients aiming to mitigate side effects or who prefer a pill over the injectable option. Semaglutide is the main ingredient in the new Wegovy pill as well as injectable Wegovy and Ozempic.
"We're excited to find ways to continue bringing branded treatments to the platform across specialties. More choice on the platform is the best thing for customers everywhere," said Hims CEO Andrew Dudum in a statement.
Novo and Hims had a partnership in 2025 allowing the telehealth company to offer injectable Wegovy, but the two companies walked away with Novo saying Hims had wrongfully marketed versions of its medicine. Dudum accused Novo of attempting to control how clinicians at Hims make decisions.
By tailoring its offering for patients with side effects or an aversion to needles, Gaston Kroub, a patent lawyer in New York, said Hims is positioning the oral product as another personalized option, widening the scope of personalization under the FDA’s framework.
"HIMS has shown a willingness to go as close to the line as possible,” he said. “It’s a strategy of saying, ‘All right, if we pop our head over the barbed wire fence, is anybody going to take a shot?’”
Novo launched the drug in the beginning of January and has seen strong demand in the U.S., where it is available on its cash-pay direct-to-consumer website.
Novo Chief Financial Officer Karsten Munk Knudsen told Reuters on Wednesday that the drugmaker is frustrated by continued mass marketing of compounded drugs, and said it was up to the U.S. regulator and politicians to address this.
The FDA in September issued a warning to Hims regarding its marketing of compounded semaglutide, stating claims like "same active ingredient as Ozempic and Wegovy" are misleading, as compounded drugs are not FDA-approved.
LILLY PILL IS NEXT UP
In addition to U.S. pricing pressure, Novo is girding for competition from Eli Lilly on the oral weight-loss front as the Indianapolis-based drugmaker expects to launch its own pill in the second quarter.
Some analysts said Lilly's pill, an experimental GLP-1, could be a next target for compounded copies. Compounding, in which pharmacies mix ingredients for specialized medicines or to copy a drug but at different dosages, has flourished as Americans chase cheaper prices for drugs.
Hims declined to comment on the drug. Lilly did not have an immediate comment.
In 2025, Hims doubled the size of its facility in New Albany, Ohio. The company said on Thursday the expansion allows Hims to provide treatments at a lower price.
In response to the Hims and Hers Health GLP-1 receptor agonist pill offering, FDA Commissioner Marty Makary says that the Food and Drug Administration will "take swift action" against companies mass-marketing illegal copycat drugs. Uppermost on his mind is undoubtedly the New England Compounding Center (NECC) in Framingham, Massachusetts whose contaminated injectable epidural steroids caused a fungal meningitis outbreak in 2012 which killed more than 64 people, including 11 here in Michigan:
Novo Nordisk shares rebound as FDA targets illegal drug copies
By Jacob Gronholt-Pedersen - February 6, 2026COPENHAGEN, Feb 6 (Reuters) - Shares in Danish drugmaker Novo Nordisk (NOVOb.CO) gained 5.4% on Friday, recovering some of the previous two sessions' steep losses, after the U.S. Food and Drug Administration (FDA) pledged to address mass-marketing of unapproved drugs.
The stock plunged nearly 8% on Thursday after telehealth company Hims and Hers Health (HIMS.N) launched a significantly cheaper $49 compounded version of Novo Nordisk's FDA-approved Wegovy weight-loss pill.
Novo's shares, which are near their lowest since Wegovy was introduced in June 2021, were 5.4% higher at 1341 GMT.
Late on Thursday, FDA Commissioner Marty Makary said on X that the agency would "take swift action" against companies mass-marketing illegal copycat drugs. "The FDA cannot verify the quality, safety or effectiveness of non-approved drugs," he said without naming any companies.
Despite the FDA statement, Bernstein analyst Christian Moore said he wasn't holding his breath for U.S. authorities to take decisive action.
"We do think people will still buy it, and don’t think the government will do anything to stop it, based on precedent," he said.
The FDA and individual states share regulatory authority over compounding pharmacies. In September, it launched a new tracker to show when ingredients were coming from FDA-inspected facilities. It also sent letters that month to companies it said were practicing deceptive direct-to-consumer advertising, including Hims, Novo, and rival Eli Lilly (LLY.N).
Novo, which on Wednesday flagged unprecedented price pressure that saw its stock plunge 17%, said on Thursday it would take "legal and regulatory action" in response to Hims' announcement but declined to elaborate further on Friday.
Eli Lilly, which is awaiting a U.S. regulatory decision on its weight-loss pill orforglipron, was also critical of the launch announcement.
"Patients deserve better than untested knockoffs that are sold without clinical evidence that they even work," a Lilly spokesperson said in an email to Reuters on Thursday before Makary's public post.A Hims spokesperson said on Thursday the company had not compromised on safety or efficacy and used a technology based on liposomes intended to support absorption, in response to similar criticisms from Novo.
Lilly's shares, which had ended the prior session down about 8%, rose 3.8% in premarket trading.
($1 = 6.3327 Danish crowns)
Hims & Hers Health folds:
https://x.com/HimsHersComms/status/2020207947645911214
PostHims & Hers Comms
@HimsHersCommsSince launching the compounded semaglutide pill on our platform, we’ve had constructive conversations with stakeholders across the industry. As a result, we have decided to stop offering access to this treatment. We remain committed to the millions of Americans who depend on us for access to safe, affordable, and personalized care.
This may change in March, when Novo Nordisk's compound patent expires.
Novo Nordisk filed suit against Hims & Hers:
Novo Nordisk sues Hims & Hers over patent infringement
By Stine Jacobsen - February 9, 2026COPENHAGEN, Feb 9 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab said on Monday it has filed a lawsuit against U.S. telehealth company Hims & Hers (HIMS.N), opens new tab for infringing on the Danish group's patents.
"Novo Nordisk is asking the court to permanently ban Hims from selling unapproved, compounded drugs that infringe our patents, and is seeking to recover damages," the Danish drugmaker said in a statement.
The move comes after Hims on Saturday cancelled the launch of a $49 copy of a weight-loss pill from Novo Nordisk and the U.S. Food and Drug Administration.
The Hims and Hers' reply:
https://x.com/HimsHersComms/status/2020854864666923411
PostHims & Hers Comms
@HimsHersCommsNovo Nordisk’s lawsuit is a blatant attack by a Danish company on millions of Americans who rely on compounded medications for access to personalized care. Once again, Big Pharma is weaponizing the US judicial system to limit consumer choice. This lawsuit attacks more than just one medication or company – it directly assaults a well-established, vital component of US pharmacy practice that has improved patient care for everything from obesity to infertility to cancer. Hims & Hers has a long history of providing safe access to personalized healthcare to millions of Americans, and we will continue to fight to provide choice, affordability, and access.
8:38 AM · February 9, 2026
Hims & Hers Health falls on its financial sword:
Hims & Hers forecasts first-quarter sales below estimates, shares fall
By Sneha S K in Bengaluru; Editing by Alan Barona - February 23, 2026Summary
- Shares fall 7% after hours
- Personalized weight-loss products generate $65 million headwind in Q1
- Overseas expansion to boost growth in non-weight-loss business
Feb 23 (Reuters) - Online telehealth company Hims & Hers Health (HIMS.N), which sells weight-loss drugs, hormone replacement therapies and health services, on Monday forecast first-quarter revenue below estimates, pushing its shares down 7% in after-hours trading.
The company said that the first quarter would be facing a $65 million burden from changes in the shipping of weight-loss products, which must be personalized for each prescription based on U.S. law.
Hims and Hers has grown rapidly as customers flocked to its cheap weight-loss drugs, which include compounded injectable versions of Novo Nordisk's highly popular Wegovy. Since those drugs are no longer in shortage, Hims is only allowed to make the medicines for customers if the dosage or ingredients are personalized.
Hims' efforts to launch compounded copies of Novo's new Wegovy pill at an introductory price of $49 per month were cut down earlier this month by the U.S. Food and Drug Administration, which said it would take action against it and other companies and referred Hims to the Department of Justice. Hims said in a regulatory filing that it is unclear what actions the regulators and DOJ may pursue. Novo also filed a patent suit against the company.
The stock is down 52% so far this year. Still, the company gave a 2026 outlook with the midpoint above analysts' estimates and vowed to stay on course.
"We plan to continue to operate like we always have," said CEO Andrew Dudum, who added the company is systematically broadening and diversifying its offerings. "It's important to remember that the majority of our revenue and profitability is driven by offerings outside of weight loss."
Hims and Hers forecast revenue of $600 million to $625 million for the first quarter, missing estimates of $653.11 million, according to data compiled by LSEG.
Hims also expects 2026 revenue to be in the range of $2.7 billion to $2.9 billion, compared to estimates of $2.74 billion.
REGULATORY RISK FUELS UNCERTAINTY
International expansion may help it grow but does not address the continuity of the company's weight-loss business, which remains uncertain due to regulatory risks, said Michael Cherny, an analyst at Leerink Partners.
"It would widen the long-term opportunity, but the more important component for the stock is how Hims progresses with its weight-loss business," Cherny said.
The company said its outlook gives "flexibility to lean into future investments" and said it will keep Hims on track for its 2030 target of more than $6.5 billion in revenue.
Hims last week said it will acquire Australian digital health company Eucalyptus in a deal valued at up to $1.15 billion. Analysts said the deal could accelerate growth for the company's non-weight-loss offerings.
Subscribers rose to 2.5 million, up 13% from the prior year.
It reported quarterly revenue of $617.8 million, an increase of 28% year-over-year, but below the analysts' average estimate of $619.22 million.
The company's product costs increased over 30%, a regulatory filing showed.
Hims' investment in its Super Bowl ad will also raise first-quarter operating costs, CFO Yemi Okupe said.
Novo Nordisk A/S and Hims & Hers Health Inc. have kissed and made up. Novo and Hims will announce a new partnership to sell GLP-1 receptor agonist drugs Monday:
Novo and Hims to sell obesity drugs together as feud ends, Bloomberg News reports
By Carlos Méndez in Mexico City and Mihika Sharma in Bengaluru - March 6, 2026March 6 (Reuters) - Wegovy maker Novo Nordisk (NOVOb.CO), opens new tab plans to sell its weight-loss drugs on Hims & Hers Health (HIMS.N), opens new tab platform, bringing an end to a dispute between the two companies that escalated into a legal battle last month, Bloomberg News reported on Friday.
Hims shares surged 39% in after-hours trading after the report.
The report comes nearly a month after Novo sued Hims over patent infringement following the U.S. telehealth firm's launch, and then cancellation, of a $49 copy of Novo's obesity pill.
The U.S. Food and Drug Administration had also threatened action against Hims.
Novo and Hims plan to announce a new partnership as soon as Monday, the report said, citing a person familiar with the matter.
Last year, Novo ended a short-lived agreement to sell its Wegovy weight-loss drug through Hims over the company's marketing tactics and continued sales of Wegovy copies.
A Novo spokesperson said in an e-mailed statement the company is "always in conversation with companies that can help improve patient access to FDA-approved medicines".
Hims did not immediately respond to a request for comment.
The power of the greenback on full display! 😍
Get MHF Insights
News and tips for your healthcare freedom.
We never spam you. One-step unsubscribe.
Sponsors
J & DE Family Charitable Fund
Friends
of MHF
Kelly Grotendiek
Philip Harbach
Dale Johnson
Drs. Jeffrey and Joni Jones
Vickie Kahle
Tammy Kipen
Marlin & Kathy Klumpp
Melanie Kurdys
Ruth Nobel
Patrick Peterson
Stephanie Poortenga
Jeanne Smit
Ben and Hope Staal
John Tuinstra
Jacki VanHuis
Sandy Walker
Sign Up for MHF Insights to keep up on the latest in Michigan Health Policy
